Strategic focus Target high-value medical device collaborations and M&A activity given history of asset sales and leadership changes; leverage interest from large incumbents and strategic buyers in electrophysiology and PEF tech to open co-development or licensing discussions.

Financing momentum Recent $100M Series C funding and high-profile leadership appointments indicate strong investor confidence and potential for partnerships, co-development, or contract manufacturing opportunities as the company scales commercialization globally.

Non-thermal edge CENT AURI’s non-thermal irreversible ablation with reduced muscle stimulation presents a compelling value proposition for electrophysiology clinics seeking safer, less invasive energy-based therapies; pitch feasibility studies and clinical collaboration opportunities with hospital networks.

Regulatory and market gaps US market readiness gaps exist since CENTAURI is not available for sale in the US; explore strategic partnerships, regulatory consulting, or regional distribution agreements to accelerate market entry and adoption in non-US regions.

Tech and ecosystem fit Compatibility with select focal-ablation catheters and mapping systems suggests sales opportunities through system integrators and existing EP equipment vendors; propose bundled solutions or co-marketing with compatible hardware and software providers.